The study objective is to investigate the chemopreventive efficacy of atorvastatin (20 mg) on HCC risk compared to placebo in adults with advanced fibrosis (i.e. METAVIR fibrosis stage 3-4) and high-risk PLsec (defined by pre-randomization blood-based assay). HCC risk will be measured by changes in prognostic liver secretome (PLsec) risk score after oral administration of atorvastatin for 1 year with up to 5 years post-treatment of chart monitoring.
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.